SCHEMBL8255847

SCHEMBL8255847

COc1cccc(Nc2nccc(-c3cnc(-c4cccnc4)n3C)n2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 5/20 0.59
▸ PIK3CA P42336 4/20 0.59
▸ PIK3CB P42338 4/20 0.59
▸ ABL1 P00519 6/20 0.56
▸ BCR P11274 6/20 0.56
▸ FLT1 P17948 2/20 0.56
▸ FLT4 P35916 2/20 0.56
▸ KDR P35968 2/20 0.56
▸ GSK3B P49841 4/20 0.55
▸ CDK2 P24941 3/20 0.55
▸ DYRK1A Q13627 2/20 0.55
▸ CDK4 P11802 1/20 0.55
▸ EGFR P00533 4/20 0.55
▸ PRKCA P17252 4/20 0.55
▸ SRC P12931 3/20 0.55
▸ PRKCD Q05655 3/20 0.55
▸ MEN1 O00255 1/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8253620 0.92 PRKCA (0.55) PIK3CGPIK3CAPIK3CBABL1BCR
SCHEMBL12837140 0.86 ABL1 (0.58) ABL1BCRKDREGFRPRKCA
SCHEMBL8246544 0.86 ABL1 (0.58) PIK3CGPIK3CAABL1BCRKDR
SCHEMBL7474612 0.85 PIK3CG (0.76) PIK3CGPIK3CAPIK3CBABL1BCR
SCHEMBL8252396 0.85 ABL1 (0.77) ABL1BCREGFRPRKCASRC
SCHEMBL11924749 0.83 ABL1 (0.62) ABL1BCREGFRPRKCASRC
SCHEMBL27116598 0.78 PIK3CG (0.83) PIK3CGPIK3CAPIK3CBFLT1FLT4
SCHEMBL11929046 0.78 ABL1 (0.53) ABL1BCRKDRGSK3BCDK2
SCHEMBL8246547 0.77 ABL1 (0.58) PIK3CGPIK3CAPIK3CBABL1BCR
SCHEMBL7464195 0.76 PIK3CG (0.83) PIK3CGPIK3CAPIK3CBABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150313881-A1 Therapeutic Methods for Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2015-11-05 — — US disclosed
US-20150313881-A1 Therapeutic Methods for Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2015-11-05 — — US disclosed
US-8501812-B2 Therapeutic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS (US) 2013-08-06 — — US disclosed
US-8501812-B2 Therapeutic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS (US) 2013-08-06 — — US disclosed
US-20120208846-A1 Therapeutic Methods For Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2012-08-16 — — US disclosed
US-20120208846-A1 Therapeutic Methods For Type I Diabetes UNIVERSITY OF MASSACHUSETTS 2012-08-16 — — US disclosed
US-7897572-B1 Theraputic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2011-03-01 — — US disclosed
US-7897572-B1 Theraputic methods for type I diabetes UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2011-03-01 — — US disclosed
WO-2006104983-A1 THERAPEUTIC METHODS FOR TYPE I DIABETES UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150313881-A1 Therapeutic Methods for Type I Diabetes MAPK9, IAPP, RNASE1 PIK3CG 2604/4885PIK3CA 2022/4885PIK3CB 2764/4885
US-20120208846-A1 Therapeutic Methods For Type I Diabetes MAPK9, IAPP, RNASE1 PIK3CG 2604/4885PIK3CA 2022/4885PIK3CB 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback